Description

Lorlatinib is a medication used to treat non-small cell lung cancer (NSCLC) that is ALK-positive. It works as a targeted therapy by inhibiting the activity of the anaplastic lymphoma kinase (ALK) protein, which can promote cancer cell growth.

Interpreter Notes

Interpreters should be aware that Lorlatinib may be referred to in various contexts, particularly in oncology. It is important to maintain a formal register and avoid colloquial terms. Common variants may include mispronunciations or confusion with other similar medications, so clarity is essential.

Example Sentences

EN: The oncologist prescribed Lorlatinib for the patient's advanced lung cancer.

ES: El oncólogo prescribió Lorlatinib para el cáncer de pulmón avanzado del paciente.

Common Interpreter Mistakes

Confusing Lorlatinib with other ALK inhibitors; mispronouncing Lorlatinib as 'lorlatinib'; using informal language when discussing medication.